Abstract 1891P
Background
In a subset of patients (pts), immune checkpoint inhibitors (ICIs) hold the potential to achieve lasting and sustainable responses, or even complete recoveries in pts with clear cell renal cell carcinoma (ccRCC). We sought to understand the immunogenomic determinants of these exceptional responses to ICIs.
Methods
We analyzed pre-therapy genomic and transcriptomic data in treatment-naive metastatic ccRCC pts treated with standard-of-care immunotherapies: (1) combination of PD-1/PDL1 and CTLA-4 (IO/IO), or (2) PD-1/PD-L1 inhibitor and VEGF-receptor (IO/VEGF) combination. We also compared baseline characteristics and outcomes between these cohorts and the International Metastatic RCC Database Consortium (IMDC) dataset. We defined 3 groups of pts in each cohort: (a) extreme responders (ER): pts with complete response (CR) and progression free survival (PFS) ≥ 12 months or partial response (PR) with tumor shrinkage 50% and PFS ≥ 24 months or PR with PFS ≥ 36 months; (b) intermediate responders, pts with CR and PR who were not exceptional responders (IR); (c) pts with progressive disease (PD).
Results
550 pts on IO/IO had available whole exome sequencing (WES) data while 434 pts in the IO/VEGF cohort had available WES and RNA-sequencing data. A greater proportion of pts from clinical trials had ER (25%) when compared to real-world data (6%) in the IO/IO cohort. Neither tumor mutation burden, mean HLA-I evolutionary divergence, whole genome integrity index, tumor purity nor tumor ploidy were associated with ER in the trial cohorts. In the IO/IO cohort, clonal neoantigen load (CNL) was significantly higher in ER pts (vs. IR: p=0.043; vs. PD: p=0.017). In a multivariate Cox regression, only CNL remained associated with improved PFS (p = 0.007). In the IO/VEGF cohort, ER pts had high expression of signatures for plasma cells, memory B-cell inside, and tertiary lymphoid structures (TLS). Pts with ER had higher TLS signature score compared to IR and PD using 3 different gene expression signatures.
Conclusions
Our results suggest that ER is partly mediated by clonal neoantigen-driven cytotoxic T-cell responses and TLS formation in the tumor microenvironment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1736P - Young adult lung cancer demands more attention in a low-resource area: Bangladesh perspective
Presenter: Muhammad Rafiqul Islam
Session: Poster session 23
1737P - Use of the predictive risk model LungFlagTM for lung cancer screening in screening in a Spanish reference center: A cost-effectiveness analysis
Presenter: Maria Eugenia Olmedo Garcia
Session: Poster session 23
1738P - Impact of digital platforms on exposure to tobacco and new smoking devices: A survey approach
Presenter: Diego de Haro
Session: Poster session 23
1739P - Lung cancer mortality patterns of tobacco users in the United States: A 21-year analysis (1999-2020)
Presenter: Seif Bugazia
Session: Poster session 23
1740P - Geolocation of respiratory tract cancer and its relationship with chronic exposure to PM2.5 pollutants
Presenter: Moisés González-Escamilla
Session: Poster session 23
1741P - Are physicians aware of lung cancer screening benefits and the importance of implementing this? Data from two public hospitals in Buenos Aires province, Argentina
Presenter: Valentin Vidal
Session: Poster session 23
1742P - Gender differences in incidence trends of early-onset GI cancer: The European perspective
Presenter: Irit Ben-Aharon
Session: Poster session 23
1743P - Bridging the gender gap in oncology: GEORGiNA'S quest for equality in academic research
Presenter: Khalid El Bairi
Session: Poster session 23
1744P - Socioeconomic inequalities in the diagnosis and treatment of colon cancer: A population-based English cancer registry study
Presenter: Benjamin Pickwell-Smith
Session: Poster session 23
1745P - Why do adult patients with cancer abandon treatment in India? A nationwide qualitative study to understand the perspectives of healthcare workers
Presenter: Reshma Ayiraveetil
Session: Poster session 23